Scoliosis
Conditions
Interventions
Trial A (rocuronium bromide):The ED50 and ED95 of rocuronium bromide were determined by sequential method. The initial dosage of rocuronium bromide is 8µg·kg-1·min-1, and the adjacent dosage gradient
If MEP cannot be induced, stop the infusion of rocuronium after ruling out nerve injury and the dosage of the next patient will be reduced by 0.5µg·kg-1·min-1. Sequential infusion dose diagram of rocu
Trial B (mivacurium chloride):The ED50 and ED95 of mivacurium chloride were determined by sequential method. The initial dosage of mivacurium chloride is 10µg·kg-1·min-1, and the adjacent dosage gradi
If MEP cannot be induced, stop the infusion of mivacurium after ruling out nerve injury and the dosage of the next patient will be reduced by 0.5µg·kg-1·min-1. Sequential infusion dose diagram of miv
Sponsors
The Second Affiliated Hospital of Navy Medical University
Eligibility
Sex/Gender
All
Age
12 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1. Age 12 ~ 18 years old. 2. ASA grading I~II. 3. Patients who are scheduled to undergo primary scoliosis orthopedic surgery with intraoperative neurophysiological monitoring. 4. The subject and legal guardian signed the informed consent file.
Exclusion criteria
Exclusion criteria: 1. Patients with severe cardiovascular and cerebrovascular diseases. 2. Patients with severe lung diseases and asthma. 3. Patients with severe hepatic and renal dysfunction. 4. Patients with neuromuscular diseases. 5. Patients with muscle strength grade 2 and below. 6. Patients with rocuronium bromide or mivacurium chloride allergy. 7. Patients with abnormal butyrylcholinesterase levels. 8. Patients with skin breakage at the muscle relaxation monitoring site within 3 months. 9. Patients with BMI > 28 kg/m2 or BMI<18.5 kg/m2. 10. Contraindications to MEP monitoring, such as epilepsy, pacemakers and cochlear implants.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The dosage of rocuronium bromide or mivacurium chloride and the corresponding changes in MEP waveforms; | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean arterial pressure;Heart rate;Intraoperative movement;Gender;Age;Height;Weight;American Association of Anesthesiologists (ASA) grade;Time of operation;Dose of vasoactive drug used;Leiden-surgical;Recovery time;Extubation time; | — |
Countries
China
Contacts
Public ContactZhang Yixuan
The Second Affiliated Hospital of Navy Medical University
Outcome results
None listed